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Abstract
Objective To identify and synthesise the evidence for
efficacy and cost effectiveness of topical treatments for
superficial fungal infections of the skin and nails of
the feet.
Design Systematic review.
Interventions Topical treatments for superficial
fungal infections.
Main outcome measures Cure confirmed by culture
and microscopy for skin and by culture for nails in
patients with clinically diagnosed fungal infections.
Results Of 126 trials identified in 121 papers, 72
(57.1%) met the inclusion criteria. Placebo controlled
trials yielded pooled relative risks of failure to cure
skin infections: allylamines (0.30, 95% confidence
interval 0.24 to 0.38); azoles (0.54, 0.42 to 0.68);
undecenoic acid (0.28, 0.11 to 0.74); and tolnaftate
(0.46, 0.17 to 1.22). Although meta›analysis of 11 trials
comparing allylamines and azoles showed a relative
risk of failure to cure of 0.88 (0.78 to 0.99) in favour
of allylamines, there was evidence of language bias.
Seven reports in English favoured allylamines (0.79,
0.69 to 0.91), but four reports in foreign languages
showed no difference between the two drugs (1.01,
0.90 to 1.13). Neither trial of nail infections showed
significant differences between alternative topical
treatments.
Conclusions Allylamines, azoles, and undecenoic acid
were efficacious in placebo controlled trials. There are
sufficient comparative trials to judge relative efficacy
only between allylamines and azoles. Allylamines cure
slightly more infections than azoles but are much
more expensive than azoles. The most cost effective
strategy is first to treat with azoles or undecenoic acid
and to use allylamines only if that fails.
Introduction
About 15% of the population of the United Kingdom
have fungal infections of the foot.1 The main
treatments are topical fungistatic or fungicidal
preparations, some of which are available over the
counter. We report a systematic review of randomised
controlled trials of topical antifungal treatments for
dermatophyte infections of the skin and nails of the
foot, which were designed to assess efficacy and cost
effectiveness.
Methods
Search strategy
We searched Medline, Embase, CINAHL, BIDS, the
Cochrane Controlled Trials Register, CAB›Health,
Healthstar, DARE, the NHS Economic Evaluation
Database, and Econlit to December 1997. We searched
by hand Foot, the Journal of British Podiatric Medicine,
and the British Journal of Podiatric Medicine and Surgery;
the last two are not listed in any databases. We obtained
the details of the Cochrane Skin Group’s recent search
by hand of the British Journal of Dermatology. We
searched the bibliographies of all review papers identi›
fied. To identify unpublished or unlisted trials, we con›
tacted international pharmaceutical companies and all
schools of podiatry in the United Kingdom.
Selection criteria
We considered all randomised controlled trials that
evaluated topical treatments for fungal infections of
the skin and nails of the foot. For skin infections we
included only trials that used microscopy and culture
to establish the presence of dermatophytes. For nail
infections we included only trials that used culture to
establish the presence of dermatophytes. We included
duplicate trials only once. We excluded trials covering
sites other than the foot where data related specifically
to the foot could not be extracted. Two reviewers (RH
and SEMBS) independently applied these criteria to
each trial located. No language restrictions applied.
Data extraction and quality assessment
Both reviewers independently summarised the trials
included, and they appraised their quality of reporting
using a structured data extraction tool of 12 quality cri›
teria. The criteria were: aims clearly defined; prior sam›
ple size calculation reported; inclusion and exclusion
criteria defined; subjects blinded; method of randomi›
sation defined; baseline comparability of groups
reported (age, sex, and duration of complaint);
interventions defined; outcome assessment blinded;
compliance assessed; and trial analysed by intention to
treat.2–4
Statistical analysis
For each trial we calculated the cure rates at follow up
from the reported mycological results—that is, negative
results on microscopy, and no growth of dermatophyte
in culture. We then estimated the difference, with 95%
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confidence intervals, in the proportion of patients
cured. To estimate differences between treatments we
pooled trials that evaluated similar interventions and
controls. As there was clear evidence of heterogeneity
between trials (P < 0.001), we used random effects
models. We calculated the relative risk of failure to
cure, with 95% confidence intervals.5
Economic analysis
We calculated cost effectiveness in four ways: cost per
cure of using an over the counter preparation;
marginal cost (including general practitioner’s time)
per cure of a podiatrist referring a patient to a general
practitioner for treatment with an allylamine rather
than providing an over the counter preparation;
marginal cost per cure (excluding general practition›
er’s time) of a general practitioner, once consulted, pre›
scribing an allylamine rather than an over the counter
preparation; and marginal cost per cure (excluding
general practitioner’s time) of a general practitioner,
once consulted, treating first with an azole and reserv›
ing allylamines for treatment failures.
Results
Identified trials of skin
We located 111 papers reporting trials of topical treat›
ments for fungal skin infections, and we included
65 (58.6%) of these in our review.6–10 w1›w60 As one of
these papers8 reported three distinct trials, and three
papers7 w1 w3 each reported a pair of distinct trials,
we included 70 trials in all. Thirty one trials in
29 papers6–10 w1›w24 compared a single active treatment
with placebo (see website). Twenty seven trials in 26
papers8 w2 w25›w48 compared two active treatments (see
website). Twelve trialsw49›w60 compared more than two
treatments within the same trial (see website). We
excluded the remaining 46 trials w61›w106 owing to dupli›
cate reporting, combining data from more than one
anatomical site (for example, hand and foot), or
absence of mycological testing. Responses from the
authors of provisionally excluded trials enabled us to
include just one.w29 Responses from the pharmaceu›
tical industry identified no additional studies.
Identified trials of nails
Apart from one trial (already excluded) of topical
treatments for skin and nail infections,w99 we found
seven trials evaluating the efficacy of topical treatments
for nails, and we included two of these.w107 w108 The other
five trials reported combined data from fingernails and
toenails.w109›w113 We also excluded three trials evaluating
a combination of systemic and topical treatments for
infected nails.w114›w116
Quality assessment
The mean number of quality criteria met by the 72
included trials (two for nail infections) was only 6.3 out
of 12. Only 19 trials reported the method of randomi›
sation.
9 w2 w17›w19 w22 w24 w28 w37 w40 w41 w44 w45 w49 w51 w54 w56 w60 w107
Blinded outcome assessment was reported in only
10 trials.w8 w18 w22 w30 w31 w37 w41 w49 w54 w61 Only seven trials,
however, did not report blinding of partici›
pants.8 w17 w25 w26 w32 w47 w48
Included trials of skin
The 70 trials evaluated a variety of treatments. Azoles
were assessed in 46 trials, allylamines in 27, tolnaftate
in five,w30 w44 w56›w58 and undecenoic acid in four.w24 w56 w57 w60
Ciclopiroxolamine, which is available over the counter
in the United States and parts of Europe but not in the
United Kingdom, was evaluated in two trials reported
in the same paper.w2 Griseofulvin,10 haloprogen,w30 tea
tree oil,w58 and tolciclatew21 were each evaluated in a
separate small trial. Variotin and Whitfield’s ointment
were compared with each other in one very small
trial,w41 which followed patients for 24 weeks. As no
other trial followed patients for more than 12 weeks,
no conclusions are possible about differences in
relapse rates.
All included studies reported the infecting species
identified from the initial culture. Except in one trialw27
all fungal organisms present were dermatophytes,
most commonly Trichophytum rubrum. Although our
review was restricted to trials reporting mycological
cure, no trial reported the species obtained from
patients who were not cured.
Azoles versus placebo
Meta›analysis of data from 17 trials comparing azoles
with placebos6–9 w1 w12›w20 w55 w59 estimated the pooled rela›
tive risk of failure to cure as 0.54 (95% confidence
interval 0.42 to 0.68). The concentration of these drugs
was generally 1% but 2% for miconazole.
Allylamines versus placebo
Meta›analysis of data from 12 trials comparing
allylamines (concentration of 1% in all) with placebos
estimated the relative risk of failure to cure as 0.30
(0.24 to 0.38).
Azoles versus allylamines
The efficacy of azoles seems to depend on the duration
of treatment. Ablon et al reported that 2 weeks of treat›
ment with oxiconazole cured only 27% of patients.w4
More rigorously Bergstresser et al reported a
randomised comparison showing that 1 week of treat›
ment with clotrimazole cured only 35% of patients
whereas 4 weeks of treatment cured 70%.w53 Therefore
we excluded both Ablon’s study and Bergstresser et al’s
group treated with azoles for only 1 week from our
meta›analysis of azoles versus allylamines. This left 12
trials,w27 w29 w31›w33 w36›w40 w50 w53 which included three azoles
(bifonazole, clotrimazole, and miconazole) and two
allylamines (naftifine and terbinafine). Where stated
the concentration was 1% for all agents. The frequency
of treatment was once or twice daily, generally for 4 or
more weeks. The pooled relative risk of failure to cure
of 0.88 (0.78 to 0.99) favoured allylamines and was just
significant (figure). There was, however, a statistically
significant difference between the relative risk esti›
mates from papers in English and other languages.
Eight English language reportsw29 w31 w36 w37 w39 w40 w50 w53
favoured allylamines (0.79, 0.69 to 0.91), but four
foreign language reportsw27 w32 w33 w38 showed no
difference between the two drugs (1.01, 0.90 to 1.13).
Other compounds
The three placebo controlled trials of 1% tolnaftatew56›w58
yielded a pooled relative risk of failure to cure of 0.46
(0.17 to 1.22). The two small comparative trials showed
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tolnaftate to be significantly worse than haloprogenw30
and profoundly, though not significantly, worse than
clotrimazole.w43 The four placebo controlled trials of 5%
undecenoic acid—three with just two groupsw24 w56 w57 and
one that also compared undecenoic acid with zinc
undecenoatew60—yielded a pooled relative risk of failure
to cure of 0.28 (0.11 to 0.74). Ciclopiroxolamine was
significantly better than placebo (0.14, 0.06 to 0.32)
and better than clotrimazole although not significantly
(0.89, 0.72 to 1.10).w2
Included trials of nails
In the smaller trial, two amorolfine 5% nail lacquer for›
mulations with different vehicles both achieved a cure
rate close to 90% after 6 weeks.
w108
In the larger trial,
clotrimazole solution and tea tree oil both achieved a
cure rate close to 10% after 6 months.w107
Costs and cost effectiveness
The table shows differences in cure rates and costs for
the main treatments and their cost effectiveness. So few
trials compared azoles, undecenoic acid, and tolnaftate
directly that confidence intervals for their costs per
cure must be on the basis of placebo controlled trials.
Although there are only four such trials of undecenoic
acid, their findings are much more homogeneous than
trials of other drugs. Undecenoic acid therefore yields a
significantly cheaper average cost per cure when
purchased over the counter than azoles, and a much
narrower confidence interval than tolnaftate. As azoles
cost the NHS about half the retail price, however, there
is no significant difference in NHS cost per cure
between azoles and undecenoic acid, regardless of
general practitioner’s time.
The NHS cost of allylamines is about 2.5 times that
of over the counter preparations. Although allylamines
are more efficacious than azoles, the estimated
difference in cure rate is small. Marginal analysis in the
table shows that the extra cost of the allylamines
needed to achieve this gain in efficacy is about five
times the marginal cost of the azoles. Thus one should
consider using an azole first, costing £195 for a cohort
of 100 patients, and an allylamine only if that fails.
Pooled analysis of the trials directly comparing azoles
with allylamines yielded estimated cure rates of 72%
and 80% respectively. If the expected 28 patients not
cured by azoles were then treated with an allylamine,
this would cost a further £136. The total cost would be
£331 (£4.14 for each of the 80 cured patients) rather
than the £486 (£6.08 per cured patient) needed to treat
all patients with an initial allylamine.
Discussion
Athlete’s foot is widespread and infectious. Initial treat›
ment for most patients is a topical cream or ointment.
Good evidence shows that allylamines, azoles, and
undecenoic acid are efficacious compared with
placebo. Unfortunately there is little evidence to assess
tolnaftate against placebo or to compare azoles, unde›
cenoic acid, and tolnaftate with each other.
More trials compared allylamines with azoles. The
resulting meta›analysis suggests that allylamines are
generally more efficacious, with a relative risk of failure
Bojanovsky (1985)W27
Haas (1985)W38
Sanchez Carazo (1994)W32
Vermeer (1996)W33
Del Palacio (1989)W29
Kagawa (1985)W39
Plotkin (1990)W40
Smith (1992)W36
Evans (1993)W31
Evans (1993)W37
Smith (1990)W50
Bergstresser (1993)W53
1.0 2.5 5.0 7.5 10.0
Favours
allylamines
Favours
azoles
Comparative trials of topical allylamines and topical azoles for fungal
skin infections of foot: relative risk plot summarised by random
effects model5
Cost effectiveness of alternative topical treatments for fungal skin infections of foot. Costs are in £
NHS cost Marginal NHS cost
Comparison
(No of trials)
% Pooled estimate of
difference in cure
rate (95% CI) Retail price
Excluding GP time
(unless stated) Including GP time
OTC cost per cure
(95% CI)
Per cure excluding GP
time (95% CI)
Per cure including GP
time (95% CI)
Allylamines v
placebo (12 trials)
55.6 (41.0 to 70.2) Not OTC 4.86 4.86+9.00=13.86 Not OTC 8.74 (6.92 to 11.85) 24.93 (19.74 to 33.80)
Azoles v placebo
(17 trials)
37.6 (25.3 to 49.9) 3.89 1.95 1.95+9.00=10.95 10.34 (7.80 to 15.38) 5.19 (3.91 to 7.71) 29.12 (21.94 to 43.28)
Allylamines v azoles
(12 trials)
7.9 (0.01 to 16.3) If patient is
consulting GP:
2.91−0.071*×
9.00†=2.27
If patient is
consulting podiatrist:
11.91−0.071*×
9.00†=11.27
Not OTC 28.73‡ (lower bound
13.92; no upper bound)
143§ (lower bound
69.14; no upper bound)
Undecenoic acid v
placebo (4 trials)
46.1 (31.6 to 60.6) 1.89 1.89 1.89+9.00=10.89 4.10 (3.12 to 5.98) 4.10 (3.12 to 5.98) 23.62 (17.97 to 34.46)
Tolnaftate v placebo
(3 trials)
37.6 (2.6 to 72.5) 1.83 1.83 1.83+9.00=10.83 4.87 (2.52 to 69.58) 4.87 (2.52 to 69.58) 28.80 (14.94 to 411)
OTC=over the counter; GP=general practitioner.
*Since allylamines cure 7.9% more infections than azoles on average, it is assumed that initial treatment with them will reduce consultations with GP by 7.9%.
†Average cost of consultation with GP in his or her surgery is £9.00.w118
‡When GP is considering during consultation initiated by patient or podiatrist whether to prescribe terbinafine or clotrimazole as first treatment.
§When podiatrist is considering referring patient to GP for treatment with terbinafine rather than providing clotrimazole.
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to cure of 0.88 (0.78 to 0.99). This difference is more
marked in trials reported in English (0.79, 0.69 to 0.91)
but not significant in foreign language trials. This
discrepancy could not be explained by differences in
the quality of the trials, commercial sponsorship, or the
patients’ characteristics. This suggests that by including
foreign papers in this review we have reduced English
language bias
w119
and improved the estimate of relative
risk of failure to cure.
We detected no differences in efficacy between
individual allylamines or individual azoles. As no trial
reported the species obtained from patients who were
not cured, we cannot draw conclusions about suscepti›
bility to individual compounds to help clinical decision
making. Without more evidence we recommend treat›
ment with the least expensive compound within each
class.
Although allylamines cure slightly more infections
than azoles, they are available only on prescription at
much greater cost. Hence the most cost effective strat›
egy is to treat first with an azole or undecenoic acid and
to reserve allylamines for treatment failures. To
improve on this recommendation more direct com›
parisons are needed of undecenoic acid and tolnaftate
with allylamines and azoles, and a large trial is needed
to refine our estimate of the incremental benefit of
allylamines over azoles.
Evidence about the efficacy of topical treatments
for nail infections is very sparse. Little can be
concluded about the role of these agents in curing
infected toenails. Rigorous research is overdue.
Conclusion
In summary there is little evidence to differentiate
between three popular over the counter topical
treatments for fungal skin infections. Azoles may be
more efficacious than tolnaftate. They seem, however,
no more efficacious than undecenoic acid. Evidence
shows that allylamines are slightly more efficacious
than azoles and other over the counter treatments but
at much greater cost. Thus we recommend initial treat›
ment with azoles or undecenoic acid, and the use of
allylamines only if that fails.
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Key messages
x About 15% of the population have fungal
infections of the skin or nails of the foot
x Topical allylamines—available only on
prescription—cure slightly more infections of
the skin of the foot than topical azoles or
undecenoic acid, both of which are available
over the counter
x No significant differences in efficacy between
individual allylamines or individual azoles were
found
x Allylamines cost more than over the counter
preparations and their few extra cures are
expensive, with a marginal cost per cure that is
more than five times as high as that of azoles
x Topical allylamines are therefore best reserved
for athlete’s foot that does not respond to initial
treatment with azoles or undecenoic acid
Endpiece
Do texts in English encourage
quacks?
The introduction to Theophilus Lobb’s Treatise on
the Small Pox (T Woodward, London 1741) has the
following passage:
“Some Persons have objected that Writing
physical Books in English is the Way to make
QUACKS: but the Notion is intirely groundless.
It is so far from having such a Tendency, that it
manifestly conduces to dispel the Ignorance of
many, who practice Physick, and to furnish them
with that Knowledge, which may well raise them
above that Ignominious Character.”
Lobb’s view was clearly an enlightened one;
however, I wonder how many doctors could write
their papers in Latin today?
Submitted by A P Radford, retired general
practitioner, Taunton, Somerset
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